anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
It is a birth right of babies to be breast fed and nursed. However, approximately 7.6 million babies cannot be fed with breast milk in the world every year. United Nations International Children's Emergency Fund (UNICEF) declared in its statement that, breast milk access is decreased as household income increases and in nations with high income 1 out of every 5 babies and for low or middle income nations 1 of every 25 babies never fed breast milk (UNICEF, 2018). Worldwide, among the infants under six months old, 40% is fed with breast milk only (UNICEF, 2017). According to Turkey Demographic and Health Survey data, it is found that in Turkey; breast milk feeding rate of infants under 6 months is 41% and in average breast milk feeding period is 1.8 months (TNSA, 2018).

There are many factors affecting whether an infant is breastfed. Delivery method is among one of them. While in OECD nations and in UNITED STATES OF AMERICA 32% of every delivery was caesarean (Health İndicators, 2018; ACOG, 2019), in Turkey this rate is indicated as 52% (TNSA, 2018). Caesarean delivery compared to vaginal delivery is negatively affecting the initial lactation period, milk production and suckling instinct of the infant (Hobbs et al., 2016). Esencan et al. has determined that 42.4% of women who had spinal-caesarean deliveries did not breast feed (Esencan et al., 2018).

Numerous factors are in effect for suckling and milk production. Various studies are performed in the literature it is emphasized that in order to stimulate and increase the milk production; apart from evidence based applications, breast stimulation and other techniques to cure nursing problems should be employed (Anderson et al., 2016). Becker et al. In their systematical compositions; determined that actions such as; resting, music, applying warmth to breast area, massaging, pump aided stimulations increased milk production clinically in a significant manner (Becker et al., 2016). Although applying warmth to breast area, massaging and relaxations techniques for increasing milk production and ensuring long term breast feeding are evidently lacking in the international manuals; early nursing, skin-to-skin contact together with education and support is stated to be positively affecting breast feeding (WHO, 2017; NICE, 2015). Despite all these actions taken national and international breast feeding data still is not at a favorable level. Because initiation of lactation contuniuty and increase in the period of breastfeeding depends on many factors. Education of mother starting from gestational period; care, support and consultancy services should be provided during pregnancy, birth and postpartum periods. This study has been planned in consideriation with the need for a model that includes all this service, maintenance and support, no similar study has been found in the literature that has all these components together.
FIELD: pharmaceutical industry. SUBSTANCE: invention relates to method of purification of proxanols that are nonionogenic surface-active substances based on copolymers of polyethylene glycol and polypropylene glycol (molecular mass is from 4000 to 15000 Da). Proxanols (foreign analog is pluronics) are used as components of medicinal forms used for intravenous administration or as perfusion or transfusion media. Method involves saturation of proxanol dissolved in apyretic water before filtration with carbon dioxide decreasing pH value. Then proxanol solution is filtered through membrane filter in carbon dioxide atmosphere, solution is autoclaved in sealed bottles and bottles with solution are kept at 65-70 C for 12-14 h after preliminary cooling. EFFECT: decreased content of peroxide compounds in surface-active substance solution to admissible level, apyrogenicity of solution. 4 cl, 1 tbl, 3 ex
Our study aims to validate safety and efficacy of Feroglobin capsule compared with different iron supplementations in adult subjects diagnosed with non-anemic to mild anemic iron deficiency and fatigue. Enrolled 302 participants diagnosed with non-anemic to mild anemic iron deficiency and fatigue. Group A (n = 147) received Feroglobin, Group B (n = 146) received standard of care [Haem Up Gems capsules (Ferrous fumarate) or Fericip tablets (Ferrous ascorbate)]. 293 subjects completed the study with follow-up visits on days 30, 60, and 90. Feroglobin treatment significantly increased hemoglobin levels from mean 12.43 g/dl to 13.24 g/dl in 90 days. Ferritin levels improved significantly by 442.87% compared to the standard care's 256.67%. Fatigue scale scores reduced by 47.51%, and all presenting health complaints resolved completely. Gastrointestinal symptoms observed were similar in both the groups. Both groups exhibited moderate treatment adherence. Quality of life improved in pain and general health domains, exhibiting a good tolerability. Adverse events were unrelated to the investigational products. Feroglobin serves as an efficacious therapeutic alternative for improving hemoglobin, ferritin, and reducing fatigue with low doses compared to standard of care. However, longer-term effects of low-dose require further investigations in different target groups.
The invention discloses a freeze-dried excipient, which consists of a kernel and outer layers. The kernel contains effective dose of nonvolatile medicinal active ingredient and auxiliary material, wherein the auxiliary material is a small molecular water-soluble substance and/or a long-chain water-soluble substance. The freeze-dried excipient is characterized in that: the outer layers can partially or totally wrap the kernel of the freeze-dried excipient, and the outer layers contain a Chinese medicinal volatile component and a pharmaceutically acceptable material, the melting point of which is 30 to 70 DEG C; and the number of the outer layers is 1 to 5. The invention also discloses a preparation method of the freeze-dried excipient containing the Chinese medicinal volatile component. The method for preparing the freeze-dried excipient comprises the following steps of: preparing the nonvolatile medicinal active ingredient and the other auxiliary materials into a freeze-dried excipient, mixing the Chinese medicinal volatile component and the pharmaceutically acceptable material with the melting point of 30 to 70 DEG C, heating the mixture till the mixture is liquid, quantitatively spraying the liquid to the surface of the freeze-dried excipient, and forming one or more layers of thin solid films containing the volatile component because the temperature is reduced to obtain the freeze-dried excipient. The freeze-dried excipient has the advantages of achieving instant and quick release effects in use, accurately storing the volatile component and realizing low medication safety risk; in addition, the content uniformity of the volatile component can be ensured.
System and method for minimizing pre-treatment time for person in casualty is described. This invention aims at 2-pronged approach to tackle and improve road traffic accidents and casualties occurring at home. Firstly, it aims towards making the traffic management system into intelligent system so that the emergency vehicle (EV) carrying the person shall pass smoothly without time lapse. The intent is to create a "Green Corridor" for the EV. Secondly, it aims to reduce the pre-medical checks when person in casualty arrives at healthcare centre. EV is combined with a health device called biometric for retrieving the previous medical history of a person whose data is stored in database under biometric scan. The object of pre-hospital care is to reduce the morbidity and mortality of those who are injured before the arrival at healthcare centre. The system operates in ubiquitous environment utilising AI and electronics for improving healthcare governance digitally.
Neonates exposed to Zoloft and other SSRIs or SNRIs, late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. These findings are based on post marketing reports. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome (see WARNINGS). 

Exposure during late pregnancy to SSRIs may have an increased risk for persistent pulmonary hypertension of the newborn (PPHN). PPHN occurs in 1–2 per 1,000 live births in the general population and is associated with substantial neonatal morbidity and mortality. In a retrospective case-control study of 377 women whose infants were born with PPHN and 836 women whose infants were born healthy, the risk for developing PPHN was approximately six-fold higher for infants exposed to SSRIs after the 20th week of gestation compared to infants who had not been exposed to antidepressants during pregnancy. A study of 831,324 infants born in Sweden in 1997–2005 found a PPHN risk ratio of 2.4 (95% CI 1.2–4.3) associated with patient-reported maternal use of SSRIs "in early pregnancy" and a PPHN risk ratio of 3.6 (95% CI 1.2–8.3) associated with a combination of patient-reported maternal use of SSRIs "in early pregnancy" and an antenatal SSRI prescription "in later pregnancy."

When treating a pregnant woman with ZOLOFT during the third trimester, the physician should carefully consider both the potential risks and benefits of treatment (see DOSAGE AND ADMINISTRATION). Physicians should note that in a prospective longitudinal study of 201 women with a history of major depression who were euthymic in the context of antidepressant therapy at the beginning of pregnancy, women who discontinued antidepressant medication during pregnancy were more likely to experience a relapse of major depression than women who continued antidepressant medication.
PURPOSE:To rapidly evaluate the effect of a hair growing component with high accuracy by administering a sample to measure the developing amt. of mRNA(G6PDH-mRNA) encoding glucose-6-phosphoric acid dehydrogenase of the hair follicle in the skin. CONSTITUTION:A hair growing component to be evaluated is administered to an experimental animal such as a mouse and, after the elapse of a predetermined time, the developing amt. of G6PDH-mRNA in a hair follicle is measured to be compared with that of G6PDH-mRNA in a case administering no hair growing component. The developing amt. of G6PDH-mRNA can bve quantitatively determined and measured as the relative amt. of G6PDH-mRNA in RNA prepared from a hair follicle or as the absolute amt. of G6PDH-mRNA in a definite amt. of the hair follicle. By detecting the developing amt. of G6PDH- mRNA as mentioned above, the developing amt. of phosphoric acid dehydrogenase can be measured within a short time and hair growing effect can be evaluated within a short period with high accuracy.
This is a multicenter, US-only, phase 1, open-label, dose escalation, non-randomized study of the safety, tolerability, and immunogenicity of investigational ChAd and SAM SARS-CoV-2 vaccines in healthy adult subjects. Homologous and heterologous prime-boost vaccination schedules (Stage 1), as well as boost(s) after receipt of COVID-19 EUA/licensed vaccines (Stage 2) will be examined. Subjects' willingness to receive ChAd vaccines will be assessed and documented at the time of informed consent and considered to determine group assignments. This phase 1 study will enroll 17 Stage 1 and up to 118 Stage 2 subjects. Eligible subjects will be enrolled in different groups based on their age (18-60 years old and \>60 years old) and their EUA/licensed COVID-19 vaccination status. A sentinel approach with 72-hour (Stage 1, and Stage 2, Groups 5, 6, 8-10, 12, 13-15) or 7-day observation times (Groups 7 and 11) will be used, before recruiting the remainder of each dose escalation group. Decisions about dose escalation will be determined by the SSC with consultation with the DSMB as needed after all subjects in each group have been observed through Day 8 post first study vaccination. All subjects will be followed through 12 months after their last study vaccination. Vaccinated subjects will be carefully monitored for exposure and infection to SARS-CoV-2 throughout the study. Escalation to the highest dose (10 µg) of SAM-S-TCE in younger subjects will proceed only following safety assessments of the 10 µg dose in older subjects for a period of 28 days post-vaccination. In addition, the dosage of SAM-S-TCE given as a double boost to subjects previously vaccinated with the Johnson \& Johnson/Janssen Ad26 COVID-19 EUA/licensed vaccine in Groups 8A, 8B, and 12A, 12B will be determined based on the dose escalation reactogenicity and immunogenicity results in Groups 5-7 and 9-11, respectively. After protocol version 9.0 was implemented, it was decided not to enroll subjects into Groups 7 and 8 because of competing priorities and predicted difficulties enrolling into these two groups.

The primary objectives of this study are 1) To assess the safety and tolerability of different doses of ChAd-S or ChAd-S-TCE, and SAM-S or SAM-S-TCE when administered as prime-boost in healthy naïve adult subjects, 2) To assess the safety and tolerability of different doses of ChAd-S or ChAd-S-TCE, and SAM-S or SAM-S-TCE when administered as first or second boost in healthy adult subjects previously vaccinated with an mRNA or adenoviral-vectored COVID-19 EUA/licensed vaccine. The secondary objective of this study is to assess the humoral immunogenicity of ChAd-S or ChAd-S-TCE, and SAM-S or SAM-S-TCE.
Our proposal builds upon our established, successful school-based infrastructure to determine whether a school/classroom intervention will efficiently and effectively improve asthma morbidity by reducing these exposures. Our goal is to determine the efficacy of school/classroom based environmental intervention in reducing asthma morbidity in urban schoolchildren. Our central hypothesis is that reducing classroom/school exposure to mouse allergen, mold, and particulate pollutants will decrease asthma morbidity in students with asthma. The investigators plan to test this hypothesis in an intervention study of 300 elementary students with asthma from multiple classrooms in inner-city elementary schools. Our clinical trial aims are to determine the effectiveness of a school/classroom based environmental intervention (school integrated pest management and classroom air purifying filter units within these schools) to reduce asthma morbidity. Our mechanistic aim is to test the hypothesis that effects of school/classroom-based environmental interventions on symptoms/other measures of asthma control occur through changes in gene methylation or expression in pathways (and secondarily, in genes) relevant to airway function and asthma. This will expand our understanding of asthma immunopathogenesis and create opportunities to identify potential novel targets for asthma therapy.
Participants in the waitlist control group will not receive any active intervention during the initial study period (weeks 1-9). At Week 10, this group will receive the same intervention and assessments as described in the active treatment group above.
Plate and 3 interlocked pins. A new device for fixation of femoral neck fractures.
FIELD: medicine. SUBSTANCE: method involves administering basic phytopreparation produced from medicinal fungi and herbs containing karyoclastic poisons. A dose of deoxyribonucleic acid is intramuscularly administered 1 to 3 times a day in the total amount of 0.1-0.5 g with anti-tumor phytopreparations. Antitoxic and/or anti- anemic and/or antihistamine and/or stimulation and/or immunomodulating and/or diuretic curative phytopreparations. EFFECT: differentiated action upon normal and pathologically changed cells. 2 cl, 1 tbl
1. Technical Result Production of osteoprotegerin binding protein and receptors.          2. Essence A novel polypeptide is identified capable of binding with osteoprotegerin and corresponding receptors. Nucleic acid sequences encoding the polypeptide, or a fragment thereof are also described, also the compositions for the treatment of bone diseases such as osteoporosis, bone loss,  arthritis, hypercalcemia, and Paget's disease are also provided.         3. Field of Application Bothechnology, medicine.
A method of producing Klotho protein includes preparing a Klotho plasmid DNA vector, culturing cells, transfecting the cells with the Klotho plasmid DNA vector in a cell culture medium, growing the transfected cells, and harvesting the cell culture supernatant by removing the transfected cells. The Klotho plasmid DNA vector has a mammalian selection marker and a Klotho open reading frame. The cells are primary fibroblast cells and/or mesenchymal stromal cells. A method of manufacturing a cosmetic composition includes combining Klotho protein or the cell culture supernatant with a cosmetically acceptable vehicle. A method of treating a patient to improve the condition and appearance of aging skin includes topically administering the cosmetic composition to the patient. By upregulating the Klotho gene in vitro and incorporating the Klotho protein and growth factors into a composition, transepidermal water loss, skin atrophy, and free radical damage to the skin may be addressed.
Patients who develop increased numbers of γδ+ cytotoxic T lymphocytes 2-6 months after allogeneic bone marrow transplantation are less likely to relapse than those who do not. The γδ+ T cells isolated from blood of patients with increased γδ+ T cells are CD3+CD4−CD8−CD57+, cytolytic to K562 cells, and express the Vδ1 T cell receptor phenotype. Similar γδ+ T cells can be generated in vitro by culture of donor mononuclear cells which are enriched for γδ+ T cells by immunomagnetic depletion of depleted of CD4+ and CD8+ cells. This γδ-enriched cell preparation was cultured on a combination of immobilized pan-δ monoclonal antibody and irradiated recipient B cell leukemia. After four weeks, the cultures were almost exclusively Vδ1+ CD3+CD4−CD8− cells that co-expressed activation-associated antigens CD69, CD25, and HLA-DR. Furthermore, they were cytolytic against the primary leukemia obtained from the recipient and lymphoblastic leukemia cell lines, yet had minimal cytotoxicity against normal donor-derived mononuclear cells or myeloid leulemia cell lines. These observations suggest that donor-derived cytotoxic γδ+ T cells can be generated in vitro, and may provide therapeutic potential for prevention of disease relapse.
FIELD: medicine.SUBSTANCE: group of inventions is intended to determine the toxic effect of the Mdm2 inhibitor in the individual suffering from cancer. Safety biomarker used to determine the toxic effect of the Mdm2 inhibitor is GDF-15. To determine the toxic effect of the Mdm2 inhibitor, the individual performs: (i) obtaining a biological sample taken from said individual prior to administering the Mdm2 inhibitor; (ii) determining the expression level of GDF-15 in the sample before administration; (iii) administering a dose of Mdm2 inhibitor to an individual; (iv) obtaining a biological sample taken from an individual after administering said Mdm2 inhibitor; (v) determining the expression level of GDF-15 in the sample after administration; and (vi) comparing the expression level of GDF-15 in a sample prior to administration with the expression level of GDF-15 in the sample after administration. If the expression level of GDF-15 increases by at least 25 % in said sample after administration compared to said sample before administration higher probability of patient developing thrombocytopenia in response to continuous administration of said dose of Mdm2 inhibitor. What is also presented is using the Mdm2 inhibitor in treating cancer in an individual, where either the therapeutic course of said individual is changed, if the expression level of GDF-15 in the sample after introduction is at least 25 % higher than the expression level of GDF-15 in the sample before administration; or a course of treating said individual with said Mdm2 inhibitor is unaffected if the expression level of GDF-15 in the sample after administration is less than 25 % higher than the expression level of GDF-15 in the sample before administration. Also provided are kits for predicting the probability of developing a patient suffering cancer, thrombocytopenia in response to treatment with a dose of the Mdm2 inhibitor, and for treating a patient suffering from cancer.EFFECT: using the group of inventions enables predicting an increase in the patient's thrombocytopenia in response to administering the Mdm2 inhibitor, as well as adjusting the treatment regimen of a patient suffering from cancer.38 cl, 4 ex, 8 dwg
An apparatus includes a movable member and a valve coupled to the movable member. The movable member is configured to be disposed within a housing of a medical device and has a first end portion and second end portion. A portion of the first end portion is configured to define a portion of a boundary of a gas chamber. The first end portion defines an opening configured to be in fluid communication between the gas chamber and an area outside the gas chamber. The second end portion is configured to be coupled to a needle configured to deliver a medicament into a body. The valve is configured to selectively allow fluid communication between the gas chamber and the area outside the gas chamber through the opening defined by the first end portion of the movable member.
Embodiments related to analyzing brain activity of a subject to identify signs associated with binocular rivalry. Sensed electrical activity of a subject's brain is received over a time period while the subject is exposed to a visual stimulus. The sensed electrical activity comprises a first frequency band associated with a first frequency of a first image presented to the subject's left eye, a second frequency band associated with a second frequency of a second image presented to the subject's right eye. A set of events in the time period is determined based on the frequency bands, wherein an event is associated with a change from a previous perceptual event to a new perceptual event. A metric for the subject is determined based on the set of events. The metric is analyzed to determine whether the subject exhibits signs associated with a condition that is associated with binocular rivalry.
This disclosure is directed towards a patient management system for selectively storing and/or sharing patient data. A wearable device may sense a condition associated with the wearer of the wearable device, and store values based on the condition for a period of time. The wearable device may determine that the wearable device is within range of another device, such that the wearable device can communicate with the other device, and output the values to the other device. Additionally, a computing device of the patient management system may receive, from a wearable device, first data associated with a condition of a wearer of the wearable device. The computing device may also receive second data associated with the condition from a sensing device. The computing device may determine a context of the wearer based on comparing the first and second data, and control output of an alert based on the context.